Product Details
| Product Name:
AZD7507 |
CAS No.:
1041852-85-0 |
| Purity:
99.09% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | AZD7507 |
| Description | AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity. |
| In vitro | AZD7507 inhibits the proliferation of 3T3 cells engineered to express CSF-1R and stimulated with CSF-1. It shows inhibitory activity against hERG and NaV1.5, with IC50s of >30 and 26 μM[1]. |
| In vivo | Xenografted mice were given liposomal clodronate (Lipclod) to selectively deplete phagocytic macrophages; AZD7507 to inhibit the activation of CSF receptor 1 (CSFR1), thereby preventing monocyte differentiation into macrophages; or appropriate vehicle alone[2]. In Lipclod-, GW2580-, and AZD7507-treated mice, we observed a significant decrease the number of CD68+ macrophages in the xenografted. Mice with CC-LP-1 and SNU-1079, but not WITT-1, xenografts demonstrated both reduced tumor volume and mass after treatment with Lipclod, GW2580, and AZD7507. Furthermore, of the 8 SNU-1079 xenografts that were palpable at 3 weeks, only 4 from the GW2580 group and 6 from the AZD7507 group were large enough to recover at week 6, as they were no longer palpable and too small to detect. In the CC-LP-1 group, only 3 of the 8 tumors were detectable at 6 weeks. (In the WITT-1 line, 7 xenografts were recovered from the GW2580 and 8 from the AZD7507 group.) Depletion of macrophages using Lipclod, GW2580, or AZD7507 in all 3 xenografted lines resulted in a reduction in murine Wnt7b expression at the mRNA level[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (220.02 mM), Sonication is recommended.
|
| Keywords | Inhibitor | AZD7507 | CSF-1R | CSF1R | CSF-1 receptor | AZD 7507 | AZD-7507 | c-Fms | inhibit | colony stimulating factor 1 receptor |
| Inhibitors Related | Phenytoin sodium | Lidocaine Hydrochloride hydrate | Lidocaine | Valproic Acid | Lidocaine hydrochloride | L-Aspartic aicd sodium | Mebeverine hydrochloride | Neratinib | Amitriptyline hydrochloride | Riluzole | Benzocaine | Nefopam hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:426-13-1
$40.00 / 25mg
-
CAS:357-70-0
$50.00 / 50mg
-
CAS:38675-10-4
$233.00 / 250mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$48.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States